Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively destroy RNA molecules that turn genetic instructions into disease-causing proteins.
Called “targeted RNA degraders,” this emerging technology will go after targets that traditional drug-development methods can’t reach.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
